N/A N=90 pLatelEts And MigRaine iN patEnt foRamen Ovale
Platelet Aggregation, Spontaneous · Migraine With Aura · Patent Foramen Ovale
Primary: Change in Migraine Characteristics — 43; 2; 17 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=268 DFN-11 Injection in Episodic Migraine With or Without Aura
Episodic Migraine
Primary: The Percentage of Subjects in the Double-blind Period Who Are Pain Free at 2 Hours After Dosing as Reported by the Subject in the eDiary — 51.0; 30.8 Percentage of…
Phase 2 N=195 Study of the Safety and Effectiveness of NXN-188 for the Treatment of Migraine Headache Without Aura
Migraine Without Aura
Primary: Headache Relief (Modified LOCF - Efficacy Evaluable Analysis Set) — 42; 30 Participants
Phase 2 N=218 A Study of LY2951742 in Participants With Migraine
Migraine Headache
Primary: Mean Change From Baseline in the Number of Migraine Headache Days in the Last 28-day Period of the 12-week Treatment Phase — -4.2; -3.0 Migraine headache days
Phase 3 N=473 Treatment of Multiple Attacks of Acute Migraine (0462-025)
Migraine Headache
Primary: Pain Relief at 2 Hours During the First Migraine Attack Period — 246; 30; 74; 52 participants
N/A N=100 A Non-Invasive Neuromodulation Device for Treatment of Migraine Headache
Migraine Headache, Episodic
Primary: Change in Number of Monthly Migraine Headache Days — -3.5; -1.1 migraine days
Phase 3 N=267 Efficacy and Safety of TMS for the Preemptive Treatment of Migraine With Aura
Migraine With Aura
Primary: Percentage of Participants Experiencing no Pain at Two Hours Post-treatment — 39; 22 percentage of participants
Phase 3 N=902 Phase 3 Study of MAP0004 in Adult Migraineurs
Migraine Disorders
Primary: Number of Subjects With Pain Relief at 2 Hours From Time of First Dose — 136; 231 participants
N/A N=568 Study of Two Digital Therapeutics for the Prevention of Episodic Migraine
Migraine · Episodic Migraine · Headache
Primary: Change in MMD (Monthly Migraine Days) — -3.04; -2.14 migraine days per month
Phase 3 N=157 MLD10 in the Prevention of Migraine in Adults
Migraine
Primary: Migraine Headache Days — 7.12; 6.92; 5.53; 4.79 Days
Phase 2 N=239 Study of NXN 188 for the Treatment of Migraine With Aura
Migraine With Aura
Primary: Time (Hours) to First Use of Rescue Medication — NA; NA; NA hours — p=0.6407
Phase 4 N=50 Trial of Comprehensive Migraine Intervention
Migraine
Primary: Migraine Functional Impairment as Measured by Score on the Headache Impact Test 6 (HIT6) Scale — 59; 56 units on a scale
Phase 3 N=1,380 Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)
Migraine
Primary: Number of Participants With Pain Freedom (PF) at 2 Hours Post-Dose — 56; 89; 101; 29 Participants — p=<0.001
N/A N=87 Greater Occipital and Supraorbital Nerve Blockade in Migraine Patients
Migraine Disorders
Primary: Change of Frequency of Headache — 5.3; 7.5 score on a scale
Phase 2 N=31 Treatment of Acute Migraine Headache in Children
Migrainous Headache
Primary: The Number of Subjects With a Numeric Rating Scale Score (NRS) of Zero at Two Hours. — 5; 12 participants — p=0.03
Phase 2 N=366 Staccato Loxapine in Migraine (Out Patient)
Migraine Headache
Primary: Pain-Relief at 2 Hours Post-treatment — 56; 65; 66 Participants
N/A N=31 Comorbidities Associated With Migraine and Patent Foramen Ovale (CAMP)
Migraine With Aura · Patent Foramen Ovale
Primary: Embolic Tracks
N/A N=60 Bronx MBCT-Migraine
Migraine
Primary: Proportion of People With "Severe" Scores on the Migraine Disability Assessment — 77.4; 89.7; 58.1; 75.9 percentage of participants — p=.027
N/A N=156 Cooling to Alleviate Migraine #3
Migraine With or Without Aura · Migraine · Migraine Headache
Primary: Pain Freedom at 2 Hours Post Treatment — 15; 14 Participants — p=0.7194
N/A N=16,789 Chronic Migraine Epidemiology and Outcomes Study
Migraine Disorders
Primary: Percentage of Participants With Episodic Migraine (EM) or Chronic Migraine (CM) — 91.2; 8.8 percentage of participants
Phase 3 N=34 Metformin for the Prevention of Episodic Migraine (MPEM)
Migraine
Primary: Headache Days — 23.64; 24.33 Days — p=0.83
Phase 2 N=16 Treatment for Migraine and Mood (Team-M)
Migraine · Depression
Primary: Treatment Session Adherence Rate — 7.88; 8 Number of sessions attended
Phase 4 N=40 Ticagrelor Therapy for RefrACTORy Migraine Study
Migraine · Headache · Migraine Headache
Primary: Total Number of Responders — 17 Participants
Phase 3 N=1,594 Maximizing Outcomes in Treating Acute Migraine
Migraine
Primary: Percentage of Subjects Reporting Headache Pain Freedom — 85; 14 Participants — p=<0.001
Phase 3 N=2,231 Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
Acute Migraine
Primary: Percentage of Participants Who Are Headache Pain Free — 28.2; 32.2; 15.3 percentage of participants — p=<0.001
Phase 4 N=245 An Efficacy and Tolerability Study of Topiramate in Participants With Migraine
Migraine
Primary: Percentage Decrease in Migraine Episodes — 48; 57; 46 Percentage decrease in migraine episodes — p=0.6207
N/A N=252 Evaluation of a Novel Device for Treatment of Migraine Headache
Migraine Without Aura · Migraine With Aura
Primary: Percentage of Participants With Reduction of Migraine Headache at 2 Hours Post Treatment — 66; 40 Participants
Phase 2 N=21 A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine
Acute Migraine
Primary: Change in Migraine Headache Pain Score From Time of Dosing (0 Minutes) — 0; 0.2; -0.8; -0.2 score on a scale — p=0.9733
Phase 3 N=1,633 A Study of Lasmiditan (LY573144) Over Four Migraine Attacks
Migraine
Primary: Percentage of Participants That Are Pain Free 2 Hours Postdose During the First Attack — 25.8; 29.3; 8.4 percentage of participants — p=<0.001
Phase 3 N=1,935 Multiple Attacks Study to Compare the Efficacy and Safety of MK-0974 With Placebo for Acute Migraine (MK-0974-031)
Migraines
Primary: Percentage of Participants Reporting Pain Freedom at 2 Hours Post-dose (First Migraine Attack) — 21.9; 25.1; 10.2 Percentage of participants — p=<0.001